In early 2026, the Adeno-associated Virus Vector-based Gene Therapy Market has surged to an estimated valuation of $5.4 billion, propelled by a revolution in synthetic capsid engineering. This year, the industry is buzzing over "Shielded Vectors," where AI-designed protein shells are being used to "camouflage" the virus from the human immune system. This innovation is a primary driver for the...